company:roche
Roche and Carmot's GLP1 pipeline
We take a look at Roche (via Carmot)'s GLP1 pipeline development, and figure out how CT-388, CT-996, and CT-868 are trending.
GLP1.Guide Staff
Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
category:news
A new risk: Kidney Cancer
New study suggests link between GLP1 Receptor Agonists (Ozempic, Mounjaro, etc) and kidney cancer.
malady:addiction
GLP1s vs. Addiction, a quick review
We trace research on GLP1s and addiction through the years and try to find studies that match the anecdotes.
drug:retatrutide
An update on Retatrutide (May 2025)
We take some time to check in on Retatrutide -- an update on how research and trials are progressing, and relevant news.
category:benefits
GLP1s lower inflammation, Psoriasis, AND increase fertility?
We look into the anti-inflammatory effects of GLP1s and their effects on issues like psoriasis and infertility.
politics
GLP1s and Tariffs, the story so far
We take a look at the various movements in GLP1 policy by the Trump administration, so far.
drug:wegovy
Wegovy in pill form is coming
Novo Nordisk is producing a pill form of Wegovy -- the only pill to be FDA approved (if/when it is) for weight loss.
drug:nimacimab
Boosting Tirzepatide with Nimacimab
Nimacimab delivers excellent results and explores a new path: drugs meant to be taken *with* other GLP1s.
company:eli-lilly
Eli Lilly suing GLP1 compounders & related companies
Eli Lilly sues many compounding-related companies in an effort to clear the market of compounded GLP1.
company:pfizer
Pfizer ends development of oral GLP1 Danuglipron
Amid heavy competition in GLP1 development, Pfizer gives up on the promise of Danuglipron, citing issues with liver related side-effects.
drug:mounjaro
Mounjaro's India launch
Eli Lilly's Mounjaro launches in India
category:news
Oral pill Orforglipron delivers stellar results in Phase 3 Trial
Eli Lilly's new drug oral GLP1 Orforglipron delivers fantastic results in phase 3 trial -- 7.6% weight loss for just a pill!